Search results for "Peripheral"

showing 10 items of 1028 documents

Ustekinumab therapy changes the transcriptional activity pattern of TGF-β1–3 genes

2019

Introduction One of the examples of genes whose expression can be altered by the action of ustekinumab is TGF-β. It is a pleiotropic cytokine whose activity affects psoriatic changes and the state of homeostasis of the whole organism. Aim To evaluate the effect of ustekinumab on the transcriptional activity of TGF-b family genes in patients with psoriatic arthritis and to check whether the results obtained can be helpful in monitoring the progress of treatment. Material and methods From total PBMCs obtained from peripheral blood of 14 patients with psoriatic arthritis, total RNA was isolated. The expression level of the TGF-β1, TGF-β2 and TGF-β3 genes was determined by RT-qPCR in real time.…

molecular markerMessenger RNAOriginal Paperbusiness.industrymedicine.medical_treatmentRNApsoriasis arthritisDermatologyPharmacologymedicine.diseasePeripheral blood mononuclear cellRC31-1245ustekinumabPsoriatic arthritisCytokineRL1-803UstekinumabmedicineImmunology and Allergytgfβ1-3businessGeneInternal medicinemedicine.drugTransforming growth factorAdvances in Dermatology and Allergology
researchProduct

Treatment of Knee Osteoarthritis with Bone Marrow-Derived Mononuclear Cell Injection: 12-Month Follow-up.

2018

Objectives To evaluate the main symptoms of knee osteoarthritis (OA) and tissue structure changes after a single dose bone marrow–derived mononuclear cell (BM MNC) intra articular injection. Case series study. Patients with knee OA Kellgren Lawrence (K-L) grade II and III received 1 injection of BM MNC. The clinical results were analyzed with the Knee injury and Osteoarthritis Outcome Score (KOOS) and Knee Society Score (KSS) before, 3, 6, and 12 months after injection. Radiological evaluation was performed with a calibrated x-ray and the magnetic resonance (MR) imaging before and 6 to 7 months postinjection. Results A total of 34 knees were treated with BM MNC injections. Mean (±SD) age of…

musculoskeletal diseasesAdultMalePathologymedicine.medical_specialtyKnee JointBiomedical EngineeringPhysical Therapy Sports Therapy and RehabilitationArticular cartilageOsteoarthritisPeripheral blood mononuclear cellSeverity of Illness IndexInjections Intra-Articular03 medical and health sciences0302 clinical medicineIntra articularClinical PapersmedicineImmunology and AllergyHumans030203 arthritis & rheumatologybusiness.industryHematopoietic Stem Cell Transplantation030229 sport sciencesMiddle AgedOsteoarthritis Kneemedicine.diseaseMagnetic Resonance ImagingRadiographymedicine.anatomical_structureTreatment OutcomeLeukocytes MononuclearFemaleBone marrowStem cellbusinessMonth follow upFollow-Up StudiesCartilage
researchProduct

New Modalities in Knee Osteoarthritis Treatment Using Autologous Bone Marrow-Derived Mononuclear Cells

2018

Abstract The clinical effects on knee osteoarthritis (OA) symptoms and tissue structure were evaluated after bone marrow-derived mononuclear cell intraarticular injection. A group of 32 patients with 34 knee joints in stage II–III osteoarthritis were treated by intraarticular injection of mononuclear cell suspension. Clinical results were obtained by KOOS (Knee Osteoarthritis Outcome Score) and KSS (Knee Society Score) scores during a 12 months follow-up period. Radiological evaluation was performed using magnetic resonance imaging. A comparison with a control group of 28 patients treated with routinely used three hyaluronic acid intra-articular injections was made. No adverse effects were …

musculoskeletal diseasesPathologymedicine.medical_specialtymesenchymal stem cellsMultidisciplinaryModalitiesGeneral interestChemistryScienceQVirulenceOsteoarthritismedicine.disease_causeAutologous bonemedicine.diseasePeripheral blood mononuclear cellknee osteoarthritisMicrobiologyAntibiotic resistanceregenerative therapyhyaluronic acidmedicinebone marrow mononuclear cellsEscherichia coliGeneProceedings of the Latvian Academy of Sciences. Section B, Natural Sciences
researchProduct

Persistence ofYersinia antigens in peripheral blood cells from patients withYersinia enterocolitica O:3 infection with or without reactive arthritis

1998

Objective To assess the persistence of bacterial antigens in peripheral blood cells from patients with Yersinia enterocolitica O:3-triggered reactive arthritis (ReA). Methods Peripheral blood samples were obtained from 20 patients with Y enterocolitica O:3 infection (11 with ReA and 9 without). These samples were studied by immunochemical techniques for the presence of Yersinia antigens at the beginning of infection and up to 4 years thereafter. Synovial fluid samples from 6 of the 11 ReA patients were also studied. Results The Yersinia antigens lipopolysaccharide and heat-shock protein (HSP) were detected in peripheral blood mononuclear cells and polymorphonuclear phagocytes from all patie…

musculoskeletal diseasesbiologyT cellImmunologyYersiniabiology.organism_classificationPeripheral blood mononuclear cellmedicine.anatomical_structureRheumatologyAntigenImmunologymedicinebiology.proteinImmunology and AllergySynovial fluidPharmacology (medical)Bacterial antigenAntibodyYersinia enterocoliticaArthritis & Rheumatism
researchProduct

MDS-191: Long-Term Efficacy and Safety of Luspatercept in Lower-Risk Myelodysplastic Syndromes (MDS): Phase 2 PACE-MDS Study

2020

Background: Luspatercept, a first-in-class erythroid maturation agent, has been investigated in patients with LR-MDS and ring sideroblasts (RS) (MEDALIST; Fenaux and Platzbecker NEJM 2020) and in an ongoing Phase 3 trial regardless of RS status (COMMANDS, NCT03682536 ). The previously reported Phase 2 trial of luspatercept (Platzbecker Lanc Onc 2017) includes subtypes of LR-MDS with and without RS, regardless of prior ESA exposure, and various EPO levels. Aims: Evaluate the long-term safety and efficacy of luspatercept in LR-MDS. Methods: Patients were IPSS low/int-1, age ≥ 18 years, Hgb NCT01749514 ; NCT02268383 ). Results: As of 13July2019, 115 patients were enrolled, of whom 108 were tre…

myalgiaCancer Researchmedicine.medical_specialtyErythemabusiness.industryMyelodysplastic syndromesPeripheral edemaPhases of clinical researchHematologymedicine.diseaseLower riskClinical trialOncologyhemic and lymphatic diseasesInternal medicinemedicinemedicine.symptomBone painbusinessClinical Lymphoma Myeloma and Leukemia
researchProduct

New Metropolitan Perspectives Transition with Resilience for Evolutionary Development

2023

This open access book conveys attention to the theme of transition towards resilience and sustainability and its evolutionary perspective that emphasizes the complexity and uncertainty that governments and society are called to address in response to the ongoing challenges. "New Metropolitan Perspective Post COVID Dynamics: Green and Digital Transition, between Metropolitan and Return to Villages’ Perspectives”, 25–27 May 2022, Reggio Calabria, Italy. The papers included in the book are grouped around the following main topics: the envisaged transition towards resilience and sustainability; the relevance of the planning dimension for defining sustainable development pathways and managing co…

open innovation European Industrial Ecosystem Technological resilience Knowledge complexity Evolutionary economy Digital Transition Sustainability transitionSettore SECS-P/06 - Economia ApplicataSettore SECS-P/01 - Economia PoliticaPeripheral areas Scientific computing and data processing Resilience and Recovery Research &amp
researchProduct

Power Loading-Induced Fatigue is Influenced by Menstrual Cycle Phase

2022

Purpose To examine the effects of fatiguing power-loading on neuromuscular properties, force production, and metabolic capacities during four phases of the menstrual cycle (MC); menstruation (M), mid-follicular (mid FOL), ovulation (OV), and mid-luteal (mid LUT). Methods Sixteen eumenorrheic women performed sessions of maximal explosive leg press (2x10 at 60%1RM load with 2 min recovery between sets). Serum hormones and neuromuscular responses were measured. Results The loading protocol significantly decreased power (between -14.2% and -12.5%; p < 0.001) and maximal force production (between MVC; -15.0% and -7.8%; p < 0.001–0.05), while decreasing activation level (between AL; -6.9% and -2.…

ovulaatiosuorituskykyeumenorrheicnaisetväsymysperipheral fatiguehormonitcentral fatigueresistance exercisekuukautiskiertohermo-lihastoimintaneuromuscularvoimaharjoitteluaineenvaihduntalihasvoima
researchProduct

Pacientu aprūpe pēc perifēro artēriju slimības

2020

Bakalaura darba tēma ir “Pacientu aprūpe pēc perifēro artēriju slimības”. Pētījuma problēma ir aktuāla, jo sirds – asinsvadu un asinsrites sistēmas slimības ir galvenais invaliditātes un priekšlaicīgas nāves cēlonis ekonomiski attīstītajās valstīs. Šo slimību medicīniskā un sociālā nozīme katru dienu palielinās, jo tās turpina attīstīties un izplatīties arvien vairāk, un tās ietekmē cilvēkus arvien jaunākā vecumā. Viena no šīm slimībām ir perifēro artēriju slimība, kuras cēlonis ir ateroskleroze 80–90% gadījumos, un kura ļoti bieži netiek diagnosticēta vai tiek diagnosticēta novēloti. Perifēro artēriju slimība ievērojami samazina cilvēka dzīves kvalitāti un var izraisīt dzīvībai bīstamas ko…

pacientsperifēro artēriju slimībaaprūpepatientperipheral artery diseaseMedicīna
researchProduct

Medical management of patients with peripheral arterial disease.

2014

Peripheral arterial disease (PAD) is one of the most frequent manifestations of atherosclerosis and is associated with atherosclerosis in the coronary and carotid arteries, leading to a highly increased incidence of cardiovascular events. Major risk factors of PAD are similar to those that lead to atherosclerosis in other vascular beds. However, there are differences in the power of individual risk factors in the different vascular territories. Cigarette smoking and diabetes mellitus represent the greatest risks of PAD. For prevention of the progression of PAD and accompanying cardiovascular events similar preventative measures are used as in coronary artery disease (CAD). However, recent d…

peripheral arterial diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolare
researchProduct

Līdzestība ārstēšanā pacientiem ar perifēro artēriju okluzīvām saslimšanām

2022

Bakalaura darba tēma ir “Līdzestība ārstēšanā pacientiem ar perifēro artēriju okluzīvām saslimšanām”. Darbs sastāv no 41 lappusēm, 6 attēliem, 1 tabulas un 6 pielikumiem. Pētījuma mērķis ir noskaidrot pacientu līdzestību perifēro artēriju okluzīvo saslimšanu ārstēšanā. Pētījumā izmantota kvantitatīvā pētniecības metode – aptaujas anketa. Pētījumam izvirzīta hipotēze – pacientu ar perifēro artēriju okluzīvo saslimšanu līdzestība ārstēšanas procesā ir daļēji apmierinoša. Pacienti ir līdzestīgi medikamentozai terapijai, bet nevēlas mainīt dzīvesveida un uztura paradumus. Bakalaura darbam izvirzītā hipotēze, ka perifēro artēriju okluzīvo saslimšanu pacientu līdzestība ir daļēja – pacienti ir lī…

peripheral arteries occlusive diseasesperifēro artēriju okluzīvās slimībaslīdzestībacomplianceMedicīna
researchProduct